Related Content
Search Google Scholar for:
|
|
Science 28 September 1984:
Vol. 225. no. 4669, pp. 1487 - 1489
DOI: 10.1126/science.6332379
|
|
Articles
Science, Vol 225, Issue 4669, 1487-1489
Copyright © 1984 by American Association for the Advancement of Science
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
JJ Mule,
S Shu,
SL Schwarz,
and
SA Rosenberg
The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) of these tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity.
- A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al. (2008)
J Natl Cancer Inst
100, 950-961
| Abstract »
| Full Text »
| PDF »
- Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors.
- H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern (2006)
J. Immunol.
177, 4288-4298
| Abstract »
| Full Text »
| PDF »
- Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo.
- P. A. Antony, C. M. Paulos, M. Ahmadzadeh, A. Akpinarli, D. C. Palmer, N. Sato, A. Kaiser, C. Heinrichs, C. A. Klebanoff, Y. Tagaya, et al. (2006)
J. Immunol.
176, 5255-5266
| Abstract »
| Full Text »
| PDF »
- Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors.
- K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello (2005)
Cancer Res.
65, 2026-2034
| Abstract »
| Full Text »
| PDF »
- Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene.
- T. Murakami, N. Tokunaga, T. Waku, S. Gomi, S. Kagawa, N. Tanaka, and T. Fujiwara (2004)
Clin. Cancer Res.
10, 3871-3880
| Abstract »
| Full Text »
| PDF »
- In Vivo Antitumor Activity of Interleukin 21 Mediated by Natural Killer Cells.
- G. Wang, M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J. Leonard, and P. Hwu (2003)
Cancer Res.
63, 9016-9022
| Abstract »
| Full Text »
| PDF »
- Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein.
- K. Shimizu, E. K. Thomas, M. Giedlin, and J. J. Mulé (2001)
Cancer Res.
61, 2618-2624
| Abstract »
| Full Text »
- Prostaglandin E2 Suppressed IL-15-Mediated Human NK Cell Function Through Down-Regulation of Common {{gamma}}-Chain.
- P. C. Joshi, X. Zhou, M. Cuchens, and Q. Jones (2001)
J. Immunol.
166, 885-891
| Abstract »
| Full Text »
| PDF »
- Antitumor Cytotoxicity Mediated by Ligand-activated Human V{{alpha}}24 NKT Cells.
- T. Kawano, T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. (1999)
Cancer Res.
59, 5102-5105
| Abstract »
| Full Text »
| PDF »
- Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
- K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule (1999)
PNAS
96, 2268-2273
| Abstract »
| Full Text »
| PDF »
- Role of Spontaneous and Interleukin-2-Induced Natural Killer Cell Activity in the Cytotoxicity and Rejection of Fas+ and Fas- Tumor Cells.
- M. Bradley, A. Zeytun, A. Rafi-Janajreh, P. S. Nagarkatti, and M. Nagarkatti (1998)
Blood
92, 4248-4255
| Abstract »
| Full Text »
| PDF »
- Treatment of B-Cell Lymphoma With Chimeric IgG and Single-Chain Fv Antibody-Interleukin-2 Fusion Proteins.
- S.-J. Liu, Y.-P. Sher, C.-C. Ting, K.-W. Liao, C.-P. Yu, and M.-H. Tao (1998)
Blood
92, 2103-2112
| Abstract »
| Full Text »
| PDF »
- Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
- R. C. Fields, K. Shimizu, and J. J. Mule (1998)
PNAS
95, 9482-9487
| Abstract »
| Full Text »
| PDF »
- Natural killer cell lines kill autologous beta 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy.
- A. Porgador, O. Mandelboim, N. P. Restifo, and J. L. Strominger (1997)
PNAS
94, 13140-13145
| Abstract »
| Full Text »
| PDF »
- Sensitization of Nude Mice Using Direct Liposome Transfer of Tumor Cell Antigens.
- T. Ariyasu, O. Ike, S. Hitomi, H. Wada, Y. Okumura, and J. Sunamoto (1996)
Journal of Bioactive and Compatible Polymers
11, 191-202
| Abstract »
- Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid.
- D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu (1995)
Reproductive Sciences
2, 762-771
| Abstract »
| PDF »
- Biomaterials and biomedical devices.
- J. Hanker and B. Giammara (1988)
Science
242, 885-892
| Abstract »
| PDF »
- A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
- S. Rosenberg, P Spiess, and R Lafreniere (1986)
Science
233, 1318-1321
| Abstract »
| PDF »
|
|
